TTR 201
Alternative Names: TTR-201Latest Information Update: 22 Jan 2025
Price :
$50 *
At a glance
- Originator Tatara Therapeutics
- Class Antineoplastics; Drug conjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 23 Oct 2024 Preclinical trials in Cancer in USA (unspecified route)
- 23 Oct 2024 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Cancer presented at the 36th European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR -2024)